Evidence map›Paper›PMID 42421489›Full record

ArticleInternational journal of urology : official journal of the Japanese Urological Association2026

Diabetes Is an Independent Risk Factor for Radiation-Induced Hematuria After Robotic Stereotactic Body Radiotherapy for Prostate Cancer.

Lucia Elting, Jamil Almohtasib, Ignacio F San Francisco, Agustín Pérez-Londoño, Ra'ad Al-Faouri, Irving Kaplan, Joe Aronovitz, Prakriti Mehta, Boris Gershman, Aria F Olumi and 1 more

Abstract read
In one paragraph

Article in International journal of urology : official journal of the Japanese Urological Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lucia EltingDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0008-4140-186X
Jamil AlmohtasibDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-5055-674X
Ignacio F San FranciscoDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Agustín Pérez-LondoñoDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-1117-1679
Ra'ad Al-FaouriDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-8586-0557
Irving KaplanDepartment of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Joe AronovitzDepartment of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Prakriti MehtaRush Medical College, Chicago, Illinois, USA.
Boris GershmanDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Aria F OlumiDivision of Urologic Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-5356-2558
Nima AghdamDepartment of Radiation Oncology, New York University Langone Hospital-Long Island, New York, New York, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the incidence, timing, and clinical predictors of radiation-induced hematuria following robotic stereotactic body radiation therapy (SBRT) for localized prostate cancer.

methodsThis retrospective single-center cohort study included 397 patients treated with robotic SBRT between 2013 and 2019 for localized prostate cancer. All patients received 36.25 Gy in 5 fractions with the urethral sparing technique. Radiation-induced hematuria was defined as gross hematuria or clinically significant microscopic hematuria without alternative etiology. Incidence, time to first event, and related interventions were assessed. Severity was graded using CTCAE version 5.0. Candidate predictors were selected based on the literature. Cox proportional hazards modeling identified clinical predictors of radiation-induced hematuria.

resultsAt a median follow-up of 56 months (IQR 29-79), 48 patients (12.1%) developed radiation-induced hematuria, occurring at a median of 30 months (IQR 19-49) after radiation treatment. Severe events (grade 3) were rare, affecting only 5 patients (1.3%). Diagnostic cystoscopy was performed in 35 patients (72.9%) and 6 patients (12.5%) required a total of 10 therapeutic interventions. Diabetes was the only independent predictor (HR 2.63, 95% CI 1.37-5.00, p = 0.004), while age, anticoagulant use, prostate volume, and Charlson Comorbidity Index showed no significant association.

conclusionRadiation-induced hematuria following robotic SBRT is predominantly low-grade and late-occurring, confirming the favorable genitourinary toxicity profile. These findings help clinicians better understand this SBRT-related toxicity and provide more accurate patient counseling regarding timing and severity of potential hematuria. Diabetes was identified as an independent risk factor and may have clinical implications; however, whether optimization of glycemic control reduces hematuria risk remains uncertain and requires further investigation.

Indexed as

Diabetes ComplicationsDiabetes MellitusHematuriaProstatic NeoplasmsRadiation InjuriesRadiosurgeryAgedAged, 80 and overCystoscopyHumansIncidenceMaleMiddle AgedRetrospective StudiesRisk FactorsRobotic Surgical Proceduresdiabetes mellitusgenitourinary toxicityprostate cancerradiation toxicity‐hematuriastereotactic body radiotherapy

Identifiers

PMID42421489
PMCPMC13347103

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.